Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 17, 25 | -0.90 Decreased by -35.46% | -0.85 Decreased by -6.41% |
| Aug 6, 25 | -0.98 Decreased by -63.33% | -0.66 Decreased by -48.48% |
| May 5, 25 | -0.67 Decreased by -13.56% | -0.71 Increased by +5.31% |
| Mar 17, 25 | -0.61 Decreased by -22.00% | -0.63 Increased by +2.99% |
| Nov 12, 24 | -0.66 Decreased by -25.36% | -0.60 Decreased by -10.73% |
| Aug 8, 24 | -0.60 Decreased by -27.66% | -0.61 Increased by +1.64% |
| May 7, 24 | -0.59 Decreased by -20.41% | -0.51 Decreased by -15.69% |
| Mar 19, 24 | -0.50 Decreased by -8.70% | -0.49 Decreased by -2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -102.22 M Decreased by -58.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -110.03 M Decreased by -88.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -74.72 M Decreased by -31.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -66.45 M Decreased by -44.07% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -64.48 M Decreased by -52.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -58.51 M Decreased by -54.27% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -56.85 M Decreased by -44.37% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 11.66 M Decreased by -64.87% | -46.13 M Decreased by -17.50% | Decreased by -395.59% Decreased by -234.50% |